Merck To Collaborate With Donghao Lansheng To Pilot New Import Policy In China

On 6 Nov 2020, Merck, a leading science and technology company, announced the signing of a Letter of Intent with Donghao Lansheng (Group) Co., Ltd. The agreement, which was signed at the 3rd China International Import Expo in Shanghai, will pilot a new process that facilitates custom clearance of research materials for biomedical innovation and analytical use. This means that Merck will be able to process shipments with fewer application and technical dossier requirements Steve Vermant, managing director, Life Science, at Merck in China, says "This new policy sets an important precedent for future collaborations building on the strong support from the Chinese government." As the first and only company to be accepted by the Shanghai government to pilot this new process, Merck will be given priority to import, in collaboration with Donghao Lansheng, a certain number of research materials under the Q-license, a customs clearance permit for importing medicine. The new process will enable the license application and allow multiple shipments to China under a single license. This is an important new benefit, as each license previously allowed only one-time shipments, and a single license will now be permitted to make multiple shipments. The biomedical field was designated a strategic focus area in China's 13th Five-Year Plan and will continue to play a major role in the development of the country's 14th Five-Year Plan in 2021. The collaboration between Merck and Donghao Langsheng improves the availability of global research materials in supporting biomedical innovation in China, helping to significantly ease importation barriers on key materials needed for specialized research and ensuring more efficient flow of supplies critical to the development of life-saving therapies. The pilot further opens up the potential for Merck to propel Q-license exemption in the future, which would provide significant benefits to customers

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!